Skip to main content
Premium Trial:

Request an Annual Quote

Quest to Offer Thermo Fisher's Oncomine Dx Target Test

NEW YORK (360Dx) – Quest Diagnostics announced today that it has partnered with Thermo Fisher Scientific to offer the company's next-generation sequencing-based companion diagnostic panel for non-small cell lung cancer.

Thermo Fisher's Oncomine Dx Target Test can be used as a companion diagnostic for AstraZeneca's EGFR inhibitor Iressa (gefitinib), Pfizer's ALK and ROS1 inhibitor Xalkori (crizotinib), and the combination of Novartis' MEK inhibitor Mekinist (trametinib) and RAF inhibitor Tafinlar (dabrafenib). The panel gauges alterations in 23 genes in total. The test report not only indicates whether patients have ROS1, EGFR, and BRAF alterations linked to the three FDA-approved treatments, but also the presence or absence of variants in other genes.

Through the partnership, Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions for clinical and biopharma applications, Quest said.

The Oncomine Dx Target Test was approved by the US Food and Drug Administration in June. Thermo Fisher has said that it hopes to rapidly expand the indications for the panel to new drug/biomarker combinations as well as to new cancer types.

In October, Thermo Fisher announced it had inked a companion diagnostic deal with Blueprint Medicines to use the diagnostic panel to develop and commercialize a companion diagnostic for Blueprint's BLU-667 to identify RET fusions in non-small cell lung center patients.

Quest will perform the Oncomine Dx Target Test at its oncology center of excellence, based at the Med Fusion site in Lewisville, Texas. From this center, Quest provides evidence-based next-generation sequencing services with an emphasis on serving community oncologists, who provide the majority of cancer care in the United States.

The panel is also offered by Laboratory Corporation of America's Diagnostics and Covance businesses, NeoGeonomics Laboratories, and Cancer Genetics.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.